HIGHLIGHTS
- who: A Commentary on and colleagues from the The University of Queensland, Australia have published the Article: Commentary: Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor, in the Journal: (JOURNAL)
- future: To account for this clinical obstacle in stroke treatment future studies are needed to assess the efficacy of C5b at various time increments after ischemic injury following the model of a similar study done for PcTx1 (Pignataro et_al 2007). Due to C5b`s systemic administration and lower specificity than PcTx1 it is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.